Recent news on Vepesid

Camptosar® Evaluated in Children with Relapsed or Refractory ...  -  Feb 14, 2007
Cancer Consultants (press release),Adriamycin® (doxorubicin), Actinomycin D® (dactinomycin), Vepesid® (etoposide), Platinol® (cisplatin), and Paraplatin® (carboplatin).

Fractionated Camptosar® Plus Paraplatin® Well Tolerated in ...  -  Dec 1, 2006
Cancer Consultants (press release),A combination of VePesid® (etoposide) and Platinol® is the standard treatment option for patients with ED-SCLC. However, due to poor long-term outcomes in

Concurrent Chemotherapy, Twice-Daily Radiation and Consolidation ...  -  Nov 27, 2006
Cancer Consultants (press release),Researchers from Japan have reported that concurrent twice-daily radiotherapy and standard VePesid® (etoposide) plus Platinol® (cisplatin) followed by

No Added Benefit of Taxol® Following Chemotherapy/Radiation in ...  -  Nov 29, 2006
Cancer Consultants (press release),Patients without cancer progression following Paraplatin/VePesid/radiation therapy went on to receive consolidation Taxol. Results from this trial were

ASH: Chemotherapy Regimen Induces Complete Remissions in Burkitt's  -  Dec 11, 2006
MedPage Today,The regimen consists of dose-adjusted Vepesid (etoposide), prednisone, Oncovin (vincristine), Cytoxan (cyclophosphamide), Adriamycin (doxorubicin),

Continued Treatment with Taxotere® May Improve Outcomes for Stage ...  Oct 19, 2006
...published in Clinical Lung Cancer, the addition of Taxotere® (docetaxel) following initial treatment with Platinol® (cisplatin) and VePesid® (etoposide) may ... -Cancer Consultants (press release), Alimta® Safe and Active in Small Cell Lung Cancer  Oct 24, 2006
Standard treatment for patients with extensive SCLC include VePesid® (etoposide) plus Platinol, VePesid plus Paraplatin or Camptosar® (irinotecan) plus ... -Cancer Consultants (press release), Taxotere® Consolidation May Improve Outcomes for Stage IIIB NSCLC  Oct 24, 2006
Oncology Group (SWOG) have reported that the Taxotere® (docetaxel) consolidation following concurrent Platinol® (cisplatin/VePesid® (etoposide) and thoracic ... -Cancer Consultants (press release), Fractionated Camptosar® Plus Paraplatin® Well Tolerated in ...  -  Dec 1, 2006
Cancer Consultants (press release),A combination of VePesid® (etoposide) and Platinol® is the standard treatment option for patients with ED-SCLC. However, due to poor long-term outcomes in

Concurrent Chemotherapy, Twice-Daily Radiation and Consolidation ...  -  Nov 27, 2006
Cancer Consultants (press release),Researchers from Japan have reported that concurrent twice-daily radiotherapy and standard VePesid® (etoposide) plus Platinol® (cisplatin) followed by

No Added Benefit of Taxol® Following Chemotherapy/Radiation in ...  -  Nov 29, 2006
Cancer Consultants (press release),Patients without cancer progression following Paraplatin/VePesid/radiation therapy went on to receive consolidation Taxol. Results from this trial were

Chemotherapy and Twice-daily Radiation Therapy Promising for Small ...  -  Nov 21, 2006
Cancer Consultants (press release),Researchers from Japan recently conducted a clinical trial to evaluate a treatment combination consisting of VePesid plus Platinol (EP) in addition to

ASH: Chemotherapy Regimen Induces Complete Remissions in Burkitt's  -  Dec 11, 2006
MedPage Today,The regimen consists of dose-adjusted Vepesid (etoposide), prednisone, Oncovin (vincristine), Cytoxan (cyclophosphamide), Adriamycin (doxorubicin),

Paraplatin®, Camptosar® Supported by Neupogen® Well Tolerated ...  Aug 4, 2006
Lung Cancer . A combination of VePesid® (etoposide) and Platinol® is the standard treatment option for patients with SCLC. However ... -Cancer Consultants

Tandem Autologous Transplants Effective for High-Risk ...  Aug 21, 2006
The myeloablative regimen consisted of Alkeran, Vepesid® (etoposide) and Paraplatin® (carboplatin).The 3-year EFS was 53% for the high-dose group and 30% for ... -Cancer Consultants



Hycamtin® More Convenient than Etoposide in Small Cell Lung ...  May 5, 2006
...cisplatin (Platinol®) produce nearly equivalent outcomes with increased convenience compared to the intravenous form of etoposide (VePesid®) plus cisplatin ... - Cancer Consultants

Camptosar®/Carboplatin Improves Progression-Free Survival over ...  Apr 21, 2006
...consisting of Camptosar® (irinotecan) plus Paraplatin® (carboplatin) appears to improve progression-free survival compared with VePesid® (etoposide) plus ... - Cancer Consultants





Gemzar®/Platinol® Superior to VePesid®/Platinol® in Non-Small ...  Mar 29, 2006
Cancer, the chemotherapy combination consisting of Gemzar® (gemcitabine) plus Platinol® (cisplatin) improves outcomes compared to VePesid® (etoposide) plus ... - Cancer Consultants

Concurrent Radiation Therapy and Chemotherapy for Small Cell Lung ...  Mar 16, 2006
...small cell lung cancer (SCLC) following concurrent radiotherapy and chemotherapy with Paraplatin® (carboplatin), Taxol® (paclitaxel) and Vepesid® (etoposide ... - Cancer Consultants

Concurrent Radiation Therapy and Chemotherapy for Small Cell Lung ...  Mar 16, 2006
...recently published in the British Journal of Cancer, chemotherapy including Paraplatin® (carboplatin), Taxol® (paclitaxel), and Vepesid® (etoposide) plus ... - Cancer Consultants

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional